Semaglutide is an FDA approved once weekly injectable GLP-1 receptor agonist that has emerged as one of the most effective weight loss interventions ever studied. A 2021 New England Journal of Medicine study showed participants lost as much as 15% of body weight over 68 weeks.
Semaglutide binds to GLP-1 receptors in the brain that signal fullness. This reduces appetite and caloric intake. It also stimulates increased insulin secretion from the pancreases leading to improved blood sugar and slows gastric emptying to prolong satiety after meals. Together, these mechanisms create a powerful, multi-system approach to weight reduction that outperforms lifestyle intervention alone.
Semaglutide is a comprehensive metabolic treatment. Patients experience significant reductions in:
Semaglutide is an FDA approved once weekly injectable GLP-1 receptor agonist that has emerged as one of the most effective weight loss interventions ever studied. A 2021 New England Journal of Medicine study showed participants lost as much as 15% of body weight over 68 weeks.
Semaglutide binds to GLP-1 receptors in the brain that signal fullness. This reduces appetite and caloric intake. It also stimulates increased insulin secretion from the pancreases leading to improved blood sugar and slows gastric emptying to prolong satiety after meals. Together, these mechanisms create a powerful, multi-system approach to weight reduction that outperforms lifestyle intervention alone.
Semaglutide is a comprehensive metabolic treatment. Patients experience significant reductions in:
Semaglutide is not appropriate for patients who are pregnant, have had pancreatitis, have a personal or family history of medullary thyroid carcinoma, or have been diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A thorough provider review ensures every patient receives a safe, effective, and appropriate treatment plan.
Semaglutide is self-administered once weekly via a small subcutaneous injection, most commonly in the abdomen, thigh, or upper arm. Medicine is dispensed a month at a time and we like to see patients back in office once a month so that we can monitor for side effects as well as customize your dose to help you achieve your weight loss goal. Most patients report a noticeable reduction in appetite within the first one to two weeks. Mild nausea is the most commonly reported side effect, particularly during the early dose escalation phase, and generally resolves within a few weeks. Serious side effects are rare.
Obesity is a chronic, relapsing condition — and semaglutide is designed to support long-term management, not just short-term loss. Patients who discontinue treatment often experience gradual weight regain, which is why ongoing provider support and structured maintenance protocols are a key part of our program. For patients who achieve their goal weight, a custom maintenance dosing strategy is developed. Regular check-ins, lifestyle coaching, and labs are incorporated into the ongoing plan to ensure best results.
